Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies

Current Opinion in Immunology

Volumn 20, Issue 4, 2008, Pages 444-449

  Taylor, Ronald P ^a   Lindorfer, Margaret A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD19 ANTIGEN; CD20 ANTIBODY; CD20 ANTIGEN; FC RECEPTOR; FRESH FROZEN PLASMA; IMMUNOGLOBULIN G1 ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; OFATUMUMAB; RITUXIMAB;

ANCA ASSOCIATED VASCULITIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; B CELL LYMPHOMA; BONE MARROW BIOPSY; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; FOLLICULAR LYMPHOMA; GENETIC POLYMORPHISM; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LEUKAPHERESIS; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; VASCULITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOMA, NON-HODGKIN;

EID: 48549100414     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2008.05.011     Document Type: Review

References (55)

1. Eisenberg R., and Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol 2 (2005) 1-8
2. Sabahi R., and Anolik J.H. B-cell-targeted therapy for systemic lupus erythematosus. Drugs 66 (2006) 1933-1948
3. Looney R.J., Srinivasan R., and Calabrese L.H. The effects of rituximab on immunocompetency in patients with autoimmune disease. Arthritis Rheum 58 (2008) 5-14
4. Glennie M.J., French R., Cragg M.S., and Taylor R.P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44 (2007) 3823-3837. This comprehensive review examines in detail the mechanisms by which RTX and other anti-CD20 mAbs mediate B cell killing. It provides a clear description of the differences between 'Type I' and 'Type II' anti-CD20 mAbs with respect to their binding to CD20 on the cells and their separate cytotoxic actions.
5. Taylor R.P., and Lindorfer M.A. On the mechanism of action of rituximab in autoimmune disease: the Immune Complex Decoy Hypothesis. Nat Clin Pract Rheumatol 3 (2007) 86-95. This article evaluates the results of numerous clinical studies focused on the use of RTX in the treatment of autoimmune diseases. On the basis of analyses of these results, the Immune Complex Decoy Hypothesis is formulated and presented.
6. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., Newman R.A., Hanna N., and Anderson D.R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 (1994) 435-445
7. Kennedy A.D., Solga M.D., Schuman T.A., Chi A.W., Lindorfer M.A., Sutherland W.M., Foley P.L., and Taylor R.P. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by Rituximab. Blood 101 (2003) 1071-1079
8. Gong Q., Ou Q., Ye S., Lee W.P., Cornelius J., Diehl L., Lin W.Y., Hu Z., Lu Y., Chen Y., et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174 (2005) 817-826
9. Uchida J., Hamaguchi Y., Oliver J.A., Ravetch J.V., Poe J.C., Haas K.M., and Tedder T.F. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199 (2004) 1659-1669
10. Hamaguchi Y., Xiu Y., Komura K., Nimmerjahn F., and Tedder T.F. Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med 203 (2006) 743-753
11. Lefebvre M.-L., Krause S.W., Salcedo M., and Nardin A. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of Rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J Immunother 29 (2006) 388-397. This paper confirms that human macrophages can indeed kill RTX-opsonized cells, principally via phagocytosis.
12. Congy-Jolivet N., Probst A., Watier H., and Thibault G. Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality. Crit Rev Oncol Hematol 64 (2007) 226-233
13. Cardarelli P.M., Quinn M., Buckman D., Fang Y., Colcher D., King D., Bebbington C., and Yarranton G. Binding to CD20 by anti-B1 antibody or F(ab′)2 is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 51 (2002) 15-24
14. Manches O., Lui G., Chaperot L., Gressin R., Molens J.P., Jacob M.C., Sotto J.J., Leroux D., Bensa J.C., and Plumas J. In vitro mechanisms of action of rituximab on primary non-Hodgkin's lymphomas. Blood 101 (2002) 949-954
15. Macor P., Tripodo C., Zorzet S., Piovan E., Bossi F., Marzari R., Amadori A., and Tedesco F. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 67 (2007) 10556-10563
16. Golay J., Zaffaroni L., Vaccari T., Lazari M., Borleri G., Bernasconi S., Tedesco F., Rambaldi A., and Introna M. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated cell lysis. Blood 95 (2000) 3900-3908
17. Golay J., Manganini M., Facchinetti V., Gramigna R., Broady R., Borleri G., Rambaldi A., and Introna M. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 88 (2003) 1002-1012
18. Dall'Ozzo S., Tartas S., Paintaud G., Cartron G., Colombat P., Bardos P., Watier H., and Thibault G. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 64 (2004) 4664-4669
19. Fischer L., Penack O., Gentilini C., Nogai A., Muessig A., Thiel E., and Uharek L. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp Hematol 34 (2006) 753-759
20. Bhat R., and Watzl C. Serial killing of tumor cells by human natural killer cells-enhancement by therapeutic antibodies. PLoS ONE 2 (2007) 1-7. This article investigates the mechanisms that limit NK-cell-mediated ADCC. The results clearly indicate that killing can be exhausted at high substrate cell burden and that IL-2 treatment appears to allow the cells to 're-cycle' and resume ADCC.
21. Berdeja J.G., Hess A., Lucas D.M., O'Donnell P., Ambinder R.F., Diehl L.F., Carter-Brookins D., Newton S., and Flinn I.W. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res 13 (2007) 2392-2399
22. Bowles J.A., and Weiner G.J. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods 304 (2005) 88-99
23. Kennedy A.D., Beum P.V., Solga M.D., DiLillo D.J., Lindorfer M.A., Hess C.E., Densmore J.J., Williams M.E., and Taylor R.P. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 172 (2004) 3280-3288
24. Klepfish A., Schattner A., Ghoti H., and Rachmilewitz E.A. Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukemia. Lancet Oncol 8 (2007) 361-362
25. Williams M.E., Densmore J.J., Pawluczkowycz A.W., Beum P.V., Kennedy A.D., Lindorfer M.A., Hamil S.H., Eggleton J.C., and Taylor R.P. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 177 (2006) 7435-7443
26. Beum P.V., Kennedy A.D., Williams M.E., Lindorfer M.A., and Taylor R.P. The shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 176 (2006) 2600-2609
27. Kavai M., and Szegedi G. Immune complex clearance by monocytes and macrophages in systemic lupus erythematosus. Autoimmun Rev 6 (2007) 497-502. Although this paper does not investigate anti-CD20 mAbs, it summarizes and clarifies many of the questions concerning the activity of cells that express FcγR in SLE. This article is important in view of the increasing interest in the use of RTX in the treatment of SLE.
28. Li Y., Williams M.E., Cousar J.B., Pawluczkowycz A.W., Lindorfer M.A., and Taylor R.P. Rituximab/CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. J Immunol 179 (2007) 4263-4271
29. Laurent C., de Paiva G.R., Ysebaert L., Laurent G., March M., Delsol G., and Brousset P. Characterization of bone marrow lymphoid infiltrates after immunochemotherapy for follicular lymphoma. Am J Pathol 128 (2007) 974-980
30. Leandro M.J., Cooper N., Cambridge G., Ehrenstein M.R., and Edwards J.C.W. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatism 46 (2007) 29-36
31. Teng Y.K.O., Levarht E.W.N., Hashemi M., Bajema I.M., Toes R.E.M., Huizinga T.W.J., and van Laar J.M. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 56 (2007) 3909-3918
32. Beum P.V., Kennedy A.D., and Taylor R.P. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. J Immunol Methods 289 (2004) 97-109
33. Hatjiharissi E., Xu L., Santos D.D., Hunter Z.R., Ciccarelli B.T., Verselis S., Modica M., Cao Y., Manning R.J., and Leleu X.E.-A. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism. Blood 110 (2007) 2561-2564
34. •] demonstrate that changes in the FcγR region of anti-CD20 mAbs can enhance ADCC owing to enhanced binding to FcγRIIIa on NK cells.
35. •].
36. •].
37. Golay J., Lazzari M., Facchinetti V., Bernasconi S., Borleri G., Barbui T., Rambaldi A., and Introna M. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98 (2001) 3383-3389
38. Teeling J., French R.R., Cragg M.S., van den Brakel J., Pluyter M., Huang H., Chan C., Parren P.W., Hack C.E., Dechant M., et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin's lymphomas. Blood 104 (2004) 1793-1800
39. Teeling J.L., Mackus W.J.M., Wiegman L.J.J.M., van den Brakel J.H.N., Bees S.A., French R.R., van Meerten T., Ebeling S., Vink T., Slootstra J.W., et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 177 (2006) 362-371. This paper (and the earlier report by the same group) describes in detail the immunochemical characteristics of OFA, including why it is capable of enhanced CDC compared with RTX.
40. Bleeker W.K., Munk M.E., Mackus W.J.M., van den Brakel J.H.N., Pluyter M., Glennie M.J., van de Winkel J.G.J., and Parren P.W.H.I. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol 140 (2008) 303-312
41. Coiffier B., Lepretre S., Pedersen L.M., Gadeberg O., Fredriksen H., Van Oers M.H.J., Wooldridge J., Kloczko J., Holowiecki J., Hellman A., et al. Safety and efficacy of ofatumumab, a fully human monclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. A phase I-II study. Blood 111 (2008) 1094-1100
42. Cambridge G., Leandro M.J., Teodorescu M., Manson J., Rahman A., Isenberg D.A., and Edwards J.C. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 54 (2006) 3612-3622
43. Edwards J.C.W., and Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 6 (2006) 394-403
44. Levi M., Hack C.E., and Van Oers M.H. Rituximab-induced elimination of acquired angioedema due to C1-inhibitor deficiency. Am J Med 119 (2006) e3-e5
45. Looney R.J., Anolik J.H., Campbell D., Felgar R.E., Young F., Arend L.J., Sloand J.A., Rosenblatt J., and Sanz I. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of Rituximab. Arthritis Rheum 50 (2004) 2580-2589
46. Eisenberg R., and Looney R.J. The therapeutic potential of anti-CD20: what do B-cells do?. Clin Immunol 117 (2005) 207-213
47. Sfikakis P.P., Boletis J.N., Lionaki S., Vigklis V., Fragiadaki K.G., Iniotaki A., and Moutsopoulos H.M. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by downregulation of the T cell costimulatory molecule CD40 ligand. Arthritis Rheum 52 (2005) 501-513
48. Stasi R., Pagano A., Stipa E., and Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98 (2001) 952-957
49. Introna M., Golay J., and Barbui T. Rituximab: a new therapeutic tool for primary immune thrombocytopenic purpura?. Haematologica 88 (2003) 482-484
50. Ferraro A.J., Drayson M.T., Savage C.O.S., and MacLennan I.C.M. Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab. Eur J Immunol 38 (2008) 292-298
51. Smith K.G.C., Jones R.B., Burns S.M., and Jayne D.R.W. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis. Arthritis Rheum 54 (2006) 2970-2982
52. DiLillo D.J., Hamaguchi Y., Ueda Y., Yang K., Uchida J., Haas K.M., Kelsoe G., and Tedder T.F. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 180 (2008) 361-371. This definitive mouse model paper shows that anti-CD20 therapy has little, if any effect on the levels of existing antibodies in mice because long-lived plasma cells are not depleted by anti-CD20 mAbs. The paper has important implications for our understanding of how RTX may function in the therapy of autoimmune diseases, and why individuals who receive RTX therapy are generally not at increased risk for infections.
53. Yanaba K., Hamaguchi Y., Venturi G.M., Steeber D.A., St. Clair E.W., and Tedder T.F. B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J Immunol 179 (2007) 1369-1380
54. Hasegawa M., Hamaguchi Y., Yanaba K., Bouaziz J.-D., Uchida J., Fujimoto M., Matsushita T., Matsushita Y., Horikawa M., Komura K., et al. B-Lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 169 (2006) 954-966
55. ••], have important implications with respect to understanding the efficacy of B cell depletion therapies in human SLE.